Statistical analysis reveals a strong negative correlation between meth and un-meth levels with Rbl2 expression (r = -0.412, and r = -0.403 respectively) in breast cancer patients, whereas no significant correlation was found among Rbl2 expression and promoter methylation in control samples (Table 4). Here, RBL2 is linked to breast carcinoma.